Year 2022 / Volume 114 / Number 12
Letter
Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis

766-767

DOI: 10.17235/reed.2022.9152/2022

Lorena Carballo-Folgoso, Miriam Celada-Sendino, Andrés Castaño-García, Pedro Oliva Nacarino, Patricia Morales del Burgo, Isabel Pérez-Martínez, Ruth de Francisco, Sabino Riestra,

Abstract
Drug-induced inflammatory bowel disease (IBD) is a clinical entity on the rise due to the frequent use of immunomodulatory therapy. Here we report the case of Crohn's disease due to Ocrelizumab, a humanized anti-CD20 monoclonal antibody approved for the treatment of multiple sclerosis. The exact mechanism by which anti-CD20 antibodies can trigger IBD is unknown, but since IBD and multiple sclerosis are processes included within the spectrum of immunomediated diseases, we could suggest that Ocrelizumab could trigger IBD in genetically predisposed patients.
Share Button
New comment
Comments
No comments for this article
References
1. Zhou W, Huang Y, Lai J, et al. Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature. Gastroenterology Res. 2018 Jun;11(3):174-188.
2. Sunjaya DB, Taborda C, Obeng R, et al. First Case of Refractory Colitis Caused by Ocrelizumab. Inflamm Bowel Dis. 2020 May 12;26(6):e49.
3. Lee HH, Sritharan N, Bermingham D, et al. Ocrelizumab-Induced Severe Colitis. Case Rep Gastrointest Med. 2020 Dec 7;2020:8858378.
4. Valdivielso Cortázar E, Diz-Lois Palomares MT, Alonso Aguirre P. Crohn's disease in patients treated with etanercept. Rev Esp Enferm Dig. 2020 Jan;112(1):80-1.
5. Eckmann JD, Chedid V, Quinn KP, et al. De novo colitis associated with rituximab in 21 patients at a tertiary center. Clin Gastroenterol Hepatol 2020;18:252-3.
Related articles

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Citation tools
Carballo-Folgoso L, Celada-Sendino M, Castaño-García A, Oliva Nacarino P, Morales del Burgo P, Pérez-Martínez I, et all. Crohn’s disease induced by ocrelizumab in a patient with multiple sclerosis. 9152/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1467 visits.
This article has been downloaded 178 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 24/08/2022

Accepted: 30/08/2022

Online First: 30/09/2022

Published: 12/12/2022

Article Online First time: 37 days

Article editing time: 110 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology